

Description of NCT00382070-D2 dataset file for the NSABP-B-42 Toxicity Dataset

Publication reference: Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer Jr CE, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, and Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomized, double-blind, placebo-controlled phase 3 trial. *The Lancet Oncology*. 2019; 20: 88-99. PMID: 30509771

Supplement to: Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 2018; published online Nov 30. [http://dx.doi.org/10.1016/S1470-2045\(18\)30621-1](http://dx.doi.org/10.1016/S1470-2045(18)30621-1).

Dataset to produce the results in Table 4 of Supplementary appendix of the referenced publication. The primary dataset is provided separately NCT00382070-D1.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Variable Name	Description	Coding Scheme	Comments
SN_B42	De-identified participant ID		
Term	Reported toxicity	0 = No 1 = Yes	
AEGrade	The highest grade for the reported toxicity		